What is the price target for SBBP stock?
4 analysts have analysed SBBP and the average price target is 5.1 null. This implies a price increase of 155% is expected in the next year compared to the current price of 2.

NASDAQ:SBBP
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Strongbridge Bio Ord (SBBP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-05-25 | JMP Securities | Downgrade | Outperform -> Market Perform |
| 2021-05-25 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 174.08% | N/A 14.24% | N/A 41.98% | N/A 25.01% | N/A 54.20% | N/A 49.78% | N/A 49.01% | N/A 51.99% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -2.01 12.42% | -2.46 -22.39% | -2.21 10.16% | -0.99 55.20% | -0.54 45.45% | N/A 35.78% | N/A 50.00% | N/A 382.35% | N/A 62.92% | N/A 66.18% |
| Q3 / 21 | Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 32.00% | -0.09 16.55% | -0.08 25.82% | -0.05 27.14% | -0.05 37.50% | -0.05 44.44% |
| Revenue Q2Q % growth | 10.031M 32.49% | 10.283M 25.39% | 12.036M 41.96% | 14.586M 60.84% | 16.269M 62.18% | 17.85M 73.58% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
4 analysts have analysed SBBP and the average price target is 5.1 null. This implies a price increase of 155% is expected in the next year compared to the current price of 2.
Strongbridge Bio Ord (SBBP) will report earnings on 2022-03-02, before the market open.
The consensus EPS estimate for the next earnings of Strongbridge Bio Ord (SBBP) is -0.08 null and the consensus revenue estimate is 10.03M null.
The expected long term growth rate for Strongbridge Bio Ord (SBBP) is 42.39%.